These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9687409)

  • 1. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin.
    Portaels F; Traore H; De Ridder K; Meyers WM
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2070-3. PubMed ID: 9687409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buruli ulcer: a review of in vitro tests to screen natural products for activity against Mycobacterium ulcerans.
    Yemoa A; Gbenou J; Affolabi D; Moudachirou M; Bigot A; Anagonou S; Portaels F; Quetin-Leclercq J; Martin A
    Planta Med; 2011 Apr; 77(6):641-6. PubMed ID: 21240839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans.
    Sáez-López E; Millán-Placer AC; Lucía A; Ramón-García S
    PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011867. PubMed ID: 38573915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
    Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
    Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
    Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.
    Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L
    BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.
    Friedman ND; Athan E; Walton AL; O'Brien DP
    Antimicrob Agents Chemother; 2016 May; 60(5):2692-5. PubMed ID: 26883709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.
    Arenaz-Callao MP; González Del Río R; Lucía Quintana A; Thompson CJ; Mendoza-Losana A; Ramón-García S
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007126. PubMed ID: 30689630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.
    Rastogi N; Goh KS; Berchel M; Bryskier A
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2848-52. PubMed ID: 10991870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Robert J; Jarlier V
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.
    Johnson RC; Sáez-López E; Anagonou ES; Kpoton GG; Ayelo AG; Gnimavo RS; Mignanwande FZ; Houezo JG; Sopoh GE; Addo J; Orford L; Vlasakakis G; Biswas N; Calderon F; Della Pasqua O; Gine-March A; Herrador Z; Mendoza-Losana A; Díez G; Cruz I; Ramón-García S
    Trials; 2022 Jul; 23(1):559. PubMed ID: 35804454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnopharmacological reports on anti-Buruli ulcer medicinal plants in three West African countries.
    Tsouh Fokou PV; Nyarko AK; Appiah-Opong R; Tchokouaha Yamthe LR; Addo P; Asante IK; Boyom FF
    J Ethnopharmacol; 2015 Aug; 172():297-311. PubMed ID: 26099634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth.
    Adusumilli S; Haydel SE
    BMC Complement Altern Med; 2016 Jan; 16():40. PubMed ID: 26833071
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Kwofie SK; Dankwa B; Odame EA; Agamah FE; Doe LPA; Teye J; Agyapong O; Miller WA; Mosi L; Wilson MD
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29954088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.